Business Wire

TX-FLUENCE

12.8.2021 14:02:08 CEST | Business Wire | Press release

Share
Fluence by OSRAM Reveals Multiyear Global Research Results on Broad-Spectrum Lighting Strategies for Cannabis and Food Crops

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today the results from a series of multiyear global studies analyzing the effects of broad-spectrum white light on cannabis, Merlice tomatoes and bell peppers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210812005279/en/

The studies found that while spectrum sensitivity is cultivar-dependent, broad-spectrum lighting strategies—which include green light and other wavelengths largely absent in narrow-band spectra—improved crop yield, morphology and overall performance in selected cultivars when compared to narrow-band spectra with high ratios of red and far-red wavelengths.

“The results from our global studies show how effective broad-spectrum white light can be in improving crop performance for many cultivators around the world,” said Dr. David Hawley, principal scientist at Fluence. “Broad-spectrum strategies are about balance and flexibility in the spectrum itself as well as the overall cultivation approach. While there are certain scenarios in which narrow-band spectra, or pink light, may make sense from an energy efficiency or crop production perspective, we’ve found that many cultivars simply perform better under broad spectra across the KPIs cultivators care about most: yield, morphology and overall quality. Our latest research empowers us with new insights to assess each grower’s objectives, weigh those objectives against a facility’s unique financial, environmental and energy parameters, and then ultimately derive a tailored solution for each cultivator.”

Merlice tomatoes

A collaborative study with Wageningen University and Research (WUR)—led by researchers Leo Marcelis and Ep Heuvelink—evaluated differences in yield, morphology, development and quality for Merlice tomatoes grown with the VYPR top light series under four light spectra: PhysioSpecTM BROAD R4, PhysioSpec TM BROAD R6, PhysioSpecTM BROAD R8 and PhysioSpecTM DUAL R9B. BROAD R4, R6 and R8 all contain significant fractions of green light and other photosynthetically active wavelengths, while DUAL R9B is a narrow-band spectrum that contains almost no green light.

As researchers increased the ratio of red light in the overall spectrum, they recorded a linear decrease in yield. Compared to spectra with higher blue, red and far-red wavelengths, Merlice grown under broader spectrum lights yielded increases in fruit weight as high as 13 percent. Other tomato cultivars grown under broad-spectrum saw yield increases up to 14 percent.

Cannabis

Fluence conducted individual studies with WUR and Texas Original Compassionate Cultivation (TOCC), respectively. In the TOCC study, researchers studied Type I, Type II and Type III cannabis response to broad-spectrum R4, R6 and R8 under high PPFD. In each case, broad-spectrum R4 generated the most dry weight per plant. In Type I cannabis, PhysioSpecTM BROAD R4 generated 17 percent higher yields than the next highest yielding spectral solution, R6. Cannabis grown under broad-spectrum R4 also significantly improved morphology compared to plants cultivated under R6 or R8. Plants grown under broad-spectrum R4 were free of photobleaching in their upper buds, a development that typically occurs in plants grown with a higher fraction of red light.

In the WUR study, researchers found that in some cultivars, monoterpene and cannabinoid content, including THC, CBD and CBG, is significantly inversely proportional to the fraction of red light in the production spectrum. With these cultivars, R4 induced a 20 percent increase in cannabinoid compounds compared to spectra with red light ratios as high as 90 percent or more.

“The results of the TOCC and WUR intensity and spectrum studies are important for cannabis cultivators for two reasons,” Dr. Hawley said. “First, there is rarely a scenario in which they should grow cannabis under low PPFD. Our research continues to emphasize how much more beneficial it is to grow cannabis under higher PPFDs. Second, watch your red light ratio. There are a couple very specific cultivars and production situations that could benefit from narrow-band or high red/far-red and blue wavelengths. But it can also have detrimental effects on cannabinoid content, terpene ratios, yield and morphology, and would raise the risk of significant photobleaching of the canopy. That’s why we generally recommend growing cannabis with broad-spectrum under high PPFD.”

Bell pepper

Fluence also conducted studies with bell peppers at the Harrow Research and Development Centre in Ontario, Canada led by Dr. Xiuming Hao and Dr. Jason Lanoue. The collaborative research on bell pepper found that fruit quality significantly increased in Gina and Eurix cultivars under broad-spectrum lighting. Peppers grown under broader spectrum light increased average fruit size by up to 15 percent compared to others with higher blue and red wavelengths. An increase in the dry matter content—which is largely associated with fruit quality—also increased with increasing green light. It was also found that broad-spectrum lighting strategies proved the consistency of week-to-week production by leveling out a traditionally flush-prone crop cycle.

“Time and time again, our research with leading institutions around the world is proving that there is no universal spectral strategy for cultivators,” said David Cohen, CEO at Fluence. “For many crops and cultivars, however, it’s also showing the holistic benefits of broad-spectrum white light not just for the crop, but for a cultivator’s entire operation. That’s why we at Fluence have a multilayered approach to how we work with our cultivators. We continue to invest heavily in industry-leading research around the world. We provide cultivators with boots-on-the-ground expertise and experience in the form of our horticulture services team, and we identify the right light fixture and spectral strategy to help cultivators achieve their most important goals.”

Fluence’s ongoing global research initiatives include additional studies on strawberry, lettuce and cucumber cultivation. To learn more about Fluence and discover its latest research results, visit www.fluence.science .

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye